Vamsi Kota

Clinical trials

• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2027
• Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2027
• L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  Site PI · Recruiting · Phase 2, Phase 3

  Moleculin Biotech, Inc.

  2025–2030
• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2029